Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 8, 2011
Event: Regulation FD Disclosure regarding the publication of a pivotal clinical trial article.
Key Financial Metrics
This filing is a current report regarding a scientific publication and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No financial material changes are reported in this document. The material event is the publication of an article titled "Pivotal Trial with Plant-Cell–Expressed Recombinant Glucocerebrosidase, taliglucerase alfa, a Novel Enzyme Replacement Therapy for Gaucher Disease" in Blood, the Journal of the American Society of Hematology.
Guidance, Outlook, and Risks
- Management Commentary: The Company announced the publication of the pivotal trial results for taliglucerase alfa, a treatment for Gaucher Disease.
- Legal Disclaimer: The information contained in Item 7.01 and the attached press release (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
- Risks and Contingencies: No specific risks or contingencies are detailed in the body of this 8-K filing.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed trial results.
- Review the published article in Blood (DOI 10.1182/blood-2011-07-366955) for clinical data specifics.
- Check subsequent filings (e.g., 10-Q or 10-K) for financial impacts related to this development.